ReviewFrontiers in endocrinology2026

Glucagon-like peptide-1 and peptide YY multi-agonism with GEP44 to optimize weight loss and glycemic control while reducing gastrointestinal side effects: the future of anti-obesity pharmacotherapy?

Melissa A Burmeister et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.